BioTech AstraZeneca Posts Solid Fourth Quarter, but Offers Weak 2013 GuidanceBy Jessica SwansonMarch 17, 2014 AstraZeneca reported strong fourth-quarter results that exceeded both our expectations and those of consensus, partly driven by a low tax…